[1] Edith Lahner , Laura Conti, Bruno Annibale, et al.,”Current Perspectives in Atrophic Gastritis”.Current gastroenterology reports,vol.22,no.8,pp.38,2020.DOI: 10.1007/s11894-020-00775-1.
[2] Bray F, Ferlay J, Soerjomataram I, et al.,”Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries”, CA Cancer J Clin,vol.68,no.6,pp.394-424,2020.DOI: 10.3322/caac.21492.
[3] Lewerin C, Jacobsson S, Lindstedt G, et al.,”Serum biomarkers for atrophic gas-tritis and antibodies against Helicobacter pylori in the elderly: implications for vitamin B12, folic acid and iron status and response to oral vitamin therapy”,Scandinavian journal of gastroenterology,vol.43,no.9,pp.1050-1056,2008.DOI: 10.1080/00365520802078341.
[4] Jiajia Cui, Yuetao Liu, Yinghuan Hu, et al.,”NMR-based metabonomics and correlation analysis reveal potential biomarkers associated with chronic atrophic gastritis”, J Pharm Biomed Anal,vol.132,pp.77-86,2017.DOI: 10.1016/j.jpba.2016.09.044.
[5] Rodriguez-Castro KI, Franceschi M, Noto A, et al.,”Clinical manifestations of chronic atrophic gastritis”,Acta Biomed,vol.89,pp.88-92,2018.DOI: 10.23750/abm.v89i8-S.7921.
[6] W. Gonciarz, A. Krupa, K. Hinc et al.,”The effect of Helicobacter pylori infection and different H. pylori components on the proliferation and apoptosis of gastric epithelial cells and fibroblasts”,PLoS One,vol.14,no.8,2019.DOI: 10.1371/journal.pone.0220636.
[7] Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F, Xue C, Marinov GK, Khatun J, et al.,”Landscape of transcription in human cells”, Nature,vol.489,pp.101-108,2012.DOI: 10.1038/nature11233.
[8] Wang J, Zhu S, Meng N, He Y, Lu R, Yan GR,”ncRNA-encoded peptides or proteins and cancer”, Mol Ther,vol.27,no.10,pp.1718-1725,2019.DOI: 10.1016/j.ymthe.2019.09.001.
[9] Anastasiadou E, Jacob LS, Slack FJ,”Non-coding RNA networks in cancer”,Nat Rev Cancer,vol.18,pp.5-18,2018.DOI: 10.1038/nrc.2017.99.
[10] Tay Y, Rinn J, Pandolfi PP,”The multilayered complexity of ceRNA crosstalk and competition”Nature,vol.505,no.7483,pp.344-352,2014. DOI: 10.1038/nature12986.
[11] R. M. Mera, L. E. Bravo, M. C. Camargo et al.,”Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial”.Gut,vol.67,no.7,pp.1239-1246,2018.DOI: 10.1136/gutjnl-2016-311685.
[12] B. Holleczek, B. Schottker, H. Brenner,”Helicobacter pylori infection, chronic atrophic gastritis and risk of stomach and esophagus cancer: results from the prospective population-based ESTHER cohort study”,International Journal of Cancer, vol.146,no.10,pp.2773-2783,2020.DOI: 10.1002/ijc.32610.
[13] I. W. Deveson, S. A. Hardwick, T. R. Mercer, and J. S. Mattick,“The dimensions, dynamics, and relevance of the mammalian noncoding transcriptome,”Trends in Genetics,vol. 33, no. 7, pp. 464–478, 2017.DOI: 10.1016/j.tig.2017.04.004.
[14] B. D. Adams, C. Parsons, L. Walker, W. C. Zhang, and F. J.Slack,“Targeting noncoding RNAs in disease”,Journal of Clinical Investigation, vol. 127, no. 3, pp. 761–771, 2017.DOI: 10.1172/JCI84424.
[15] Hombach, S.; Kretz, M,”Non-coding RNAs: Classification, biology and functioning”,Adv. Exp. Med. Biol,vol.937,pp.3-17,2016.DOI: 10.1007/978-3-319-42059-2_1.
[16] Xie, C.; Yuan, J.; Li, H.;et al.,”NONCODEv4:Exploring the world of long non-coding RNA genes”,Nucleic Acids Res,pp.98-103,2014.DOI: 10.1093/nar/gkt1222.
[17] Tam, C.; Wong, J.H.; Tsui, S.K.W.;et al.,”LncRNAs with miRNAs in regulation of gastric,liver, and colorectal cancers: Updates in recent years”,Appl. Microbiol. Biotechnol,vol.103,pp.4649-4677,2019.DOI: 10.1007/s00253-019-09837-5.
[18] X. Zhou, H. Chen, L. Zhu et al.,“Helicobacter pylori infection related long noncoding RNA (lncRNA) AF147447 inhibits gastric cancer proliferation and invasion by targeting MUC2 and up-regulating miR-34c”,Oncotarget, vol. 7, no. 50,pp. 82770–82782, 2016.DOI: 10.18632/oncotarget.13165.
[19] H-Y Piao, S Guo,Y Wang,et al.,”Exosome-transmitted lncRNA PCGEM1 promotes invasive and metastasis in gastric cancer by maintaining the stability of SNAI1”,Clinical & translational oncology,vol.23,no.2,pp.246-256,2021.DOI: 10.1007/s12094-020-02412-9.
[20] Zhengwei Chen,Chaobo Xu,Xiaoming Pan,et al.,”lncRNA DSCR8 mediates miR-137/Cdc42 to regulate gastric cancer cell proliferation, invasion, and cell cycle as a competitive endogenous RNA”,Molecular therapy oncolytics,vol.22,pp.468-482,2021.DOI: 10.1016/j.omto.2021.05.010.
[21] Weiwei Chen,Yuting Li,Liliangzi Guo,et al.,”Long non-coding RNA FTX predicts a poor prognosis of human cancers: a meta-analysis”,Bioscience reports,vol.41,no.1,2021.DOI: 10.1042/BSR20203995.
[22] Li A, Qin G, Suzuki A, et al.,”Network-based identification of critical regulators as putative drivers of human cleft lip”,BMC Med Genomics,vol.12,no.1,pp.119-132,2019.DOI: 10.1186/s12920-018-0458-3.
[23] Viswambharan V,Thanseem I, Vasu MM, Poovathinal SA and Anitha A,”miRNAs as biomarkers of neurodegenerative disorders”,Biomarkers Med,vol.11,pp.151-167, 2017.DOI: 10.2217/bmm-2016-0242.
[24] Alexander Link,Wiebke Schirrmeister,Cosima Langner,et al.,”Differential expression of microRNAs in preneoplastic gastric mucosa”,Scientific reports,vol.5,pp.8270,2015.DOI: 10.1038/srep08270.
[25] Yu Jin Kim,Seongtae Jeong,Woon Yong Jung,et al.,”miRNAs as potential biomarkers for the progression of gastric cancer inhibit CREBZF and regulate migration of gastric adenocarcinoma cells”,International journal of medical sciences,vol.17,no.6,pp.693-701,2020. DOI: 10.7150/ijms.42654.
[26] Yanyan Shi,Ziwei Yang,Ting Zhang,et al.,”SIRT1-targeted miR-543 autophagy inhibition and epithelial-mesenchymal transition promotion in Helicobacter pylori CagA-associated gastric cancer”,Cell death & disease,vol.10,no.9,pp.625,2019.DOI: 10.1038/s41419-019-1859-8.
[27] Jiri Polivka Jr,Filip Janku,”Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
”,Pharmacology & therapeutics, vol.142,no.2,pp.164-175,2014. DOI: 10.1016/j.pharmthera.2013.12.004.
[28]Zhan D, Zhang X, Li J, et al.,”MTH1 Inhibitor TH287 Suppresses Gastric Cancer Development Through the Regulation of PI3K/AKT Signaling”,Cancer Biother Radiopharm,vol.35,no.3,pp.223-232,2020.DOI: 10.1089/cbr.2019.3031.
[29] Wang Q, Shi M, Sun S, et al.,”CLEC5A promotes the proliferation of gastric cancer cells by activating the PI3K/AKT/mTOR pathway”,Biochem Biophys Res Commun,vol.524,no.3,pp.656-662,2020.DOI: 10.1016/j.bbrc.2019.10.122.
[30] Cai C, Dang W, Liu S, et al.,”Anthrax toxin receptor 1/tumor endothelial marker 8 promotes gastric cancer progression through activation of the PI3K/AKT/mTOR signaling pathway”,Cancer Sci, vol.111,no.4,pp.1132-1145,2020.DOI: 10.1111/cas.14326.
[31] Song M, Wang X, Luo Y, et al.,”Cantharidin suppresses gastric cancer cell migration/invasion by inhibiting the PI3K/Akt signaling pathway via CCAT1”,Chem Biol Interact,vol.317,no.1,pp.108939-108949,2020.DOI: 10.1016/j.cbi.2020.108939.
[32] Gu Y, Fei Z, Zhu R,”miR-21 modulates cisplatin resistance of gastric cancer cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway”Anticancer Drugs,vol.31,no.4,pp.385-393,2020.DOI: 10.1097/CAD.0000000000000886.
[33] Cheng Zhang,Xiaoting Lin,Qian Zhao,et al.,”YARS as an oncogenic protein that promotes gastric cancer progression through activating PI3K-Akt signaling”,Journal of cancer research and clinical oncology,vol.146,no.2,pp.329-342,2020.DOI: 10.1007/s00432-019-03115-7.
[34] Fanguo Kong,Yansheng Shang,Xingyuan Diao,et al.,”Knockdown of NOLC1 Inhibits PI3K-AKT Pathway to Improve the Poor Prognosis of Esophageal Carcinoma”,Journal of oncology,2021.DOI: 10.1155/2021/9944132.
[35] Yuanguang Cheng,Gang Wen,Yong Sun,et al.,”Osteopontin Promotes Colorectal Cancer Cell Invasion and the Stem Cell-Like Properties through the PI3K-AKT-GSK/3b-b/Catenin Pathway”,Medical science monitor : international medical journal of experimental and clinical research,vol.25,pp.3014-3025,2019.DOI: 10.12659/MSM.913185.
[36] Na Li,Fan Yang,Dong-Yan Liu,et al.,”Scoparone inhibits pancreatic cancer through PI3K/Akt signaling pathway”,World journal of gastrointestinal oncology,vol.13,no.9,pp.1164-1183,2021.DOI: 10.4251/wjgo.v13.i9.1164.
[37] Elena Maccaroni,Riccardo Giampieri,Edoardo Lenci,et al.,”BRCA mutations and gastrointestinal cancers: When to expect the unexpected?”,World journal of clinical oncology,vol.12,no.7,pp.565-580,2021. DOI: 10.5306/wjco.v12.i7.565.
[38] Breast Cancer Linkage Consortium,”Cancer risks in BRCA2 mutation carriers”,Journal of the National Cancer Institute,vol.91,no.15,pp.1310-1316,1999.
[39] Rebelatto, T.F.; Falavigna, M.; Pozzari, M.; et al.,”Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis”,Cancer T reat. Rev,vol.80,2019.DOI: 10.1016/j.ctrv.2019.101895.
[40] Hänninen, U.A.; Katainen, R.; Tanskanen, T.;et al.,”Exome-wide somatic mutation characterization of small bowel adenocarcinoma”,PLoS Genet,vol.14,no.3,2018.DOI: 10.1371/journal.pgen.1007200.
[41] Quaas, A.; Heydt, C.; Waldschmidt, D.;et al.,”Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma”,BMC Gastroenterol,vol.19,no.1,pp.21,2019.DOI: 10.1186/s12876-019-0942-z.
[42] Changzheng Du,Yifan Peng,Yiping He,et al.”Low levels of BRCA1 protein expression predict a worse prognosis in stage I-II colon cancer”,The International journal of biological markers,vol.36,no.1,pp.47-53,2021.DOI: 10.1177/1724600820986572.
[43] Mauri G, Sartore-Bianchi A, Russo AG, et al.,”Early-onset colorectal cancer in young individuals”,Mol Oncol,vol.13,no.2,pp.109-131,2019.DOI: 10.1002/1878-0261.12417.